First Gene Therapy for Hemophilia B, CSL's HEMGENIX®, Approved by the European Commission

 Global biotechnology leader CSL (ASX: CSL) Monday announced that the European Commission has granted conditional marketing authorization (CMA) for HEMGENIX® (etranacogene dezaparvovec), the first and only one-time gene therapy for the treatment of severe and moderately severe hemophilia B (congenital Factor IX deficiency) in adults without a history of Factor IX inhibitors.